Lund, Sweden, 18:00 CET, 15 March 2021 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, has pursuant to the authorization granted by the annual general meeting on 19 May 2020, through a resolution by the board of directors of BONESUPPORT HOLDING AB (“BONESUPPORT”) resolved to issue and immediately thereafter repurchase 55,000 series C shares. The shares are issued and repurchased in accordance with the share saving program LTI 2020, which was adopted by the annual general meeting on 19 May 2020.
Pursuant to the authorization granted by the annual general meeting on 19 May 2020, the board of directors of BONESUPPORT has resolved to issue 55,000 series C shares to Svenska Handelsbanken AB. The subscription price per share amounts to SEK 0.625, which corresponds to the quota value of the shares. Furthermore, the board of directors has resolved to immediately repurchase all 55,000 series C shares from Svenska Handelsbanken AB at a price corresponding to the subscription price.
The purpose of the issue and the repurchase of series C shares is to, when the series C shares have been converted to ordinary shares, ensure delivery of performance shares to employees within the BONESUPPORT group who are participating in the share saving program LTI 2020, which was adopted by the annual general meeting on 19 May 2020. Allotment of performance shares shall take place within 30 days from the publication of the year-end report for the financial year 2023.
Since previously, BONESUPPORT holds 1,235,000 own series C shares. The series C shares carry one-tenth of a vote per share and do not entitle to dividends.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
+46 (0) 708 76 87 87
This information was submitted for publication, through the agency of the contact persons set out above, at 18.00 CET on 15 March 2021.
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 181 million in 2020. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.